Year-in-review: How the USPTO was Hallowed Out in 2025
How the USPTO was Hollowed Out in 2025
New survey shows Americans want patent reform
Keytruda Qlex: Where’s the invention?
Two bipartisan bills target patent abuse
Still Overpatented, Still Overpriced
Merck’s Scheme to Product Hop Keytruda
How Celgene and Bristol Myers Squibb Used Volume Restrictions to Delay Revlimid Competition
How Pharma and Its Consultants Abuse the Patent System
We Need More Drug Patent Data